1.Generalized Epilepsy with Febrile Seizures Plus(GEFS+) and a Mutation in the Voltage-gated Sodium(Na+)-Channel Beta 1 Subunit Gene(SCN1B).
Journal of the Korean Child Neurology Society 2000;8(1):27-32
PURPOSE: It was reported that gene locus for generalized epilepsy with febrile seizures plus(GEFS+) exist in chromosome 19q13.1, and has relationship with a 387 C G mutation in the SCN1B gene. This study is to determine whether there is the 387 C G mutation in the children with GEFS+ and simple febrile seizures(FS). METHODS: The sample group consisted of 16 patients with GEFS+ and 10 patients with FS who were diagnosed by our department of pediatrics from Jan. 1998 to Dec. 1999. The control group consisted of 15 children who do not have seizure disorders. Genomic DNA was extracted from peripheral blood and a segment of the SCN1B exon 3 was amplified by PCR technique. Purified PCR products were treated with restriction enzyme, Hin P1. The restriction pattern was analyzed by sequencing analysis. RESULTS: Sixty nine%(11 of 16) patients with GEFS+ had family history for epilepsy, and epilepsy phonotypes were generalized tonic-clonic seizures in 82%(13 of 16), on the other hand 12%(2 of 16) and 6%(1 of 16) had absences and atonic seizures respectively. EEG findings showed generalized spike and wave in the all patients with GEFS+. in this study, however we could not observe a 387 C-->G mitation of the SCN1B in the children with GEFS+ and febrile seizures. CONCLUSION: The gene for GEFS+ may have a heterogenetic characteristics, and there may be racial differences in mutation frequency. Expanded studies involving large number of different families are required.
Child
;
DNA
;
Electroencephalography
;
Epilepsy
;
Epilepsy, Generalized*
;
Exons
;
Hand
;
Humans
;
Mutation Rate
;
Pediatrics
;
Polymerase Chain Reaction
;
Seizures
;
Seizures, Febrile*
2.Efficacy and clinical observation of Shenling Baizhu Pill in treating irritable bowel syndrome
Zhe REN ; Jiangnan REN ; Yutian WU
Chinese Journal of Primary Medicine and Pharmacy 2015;(10):1510-1513,1514
Objective To observe the clinic efficacy of Shenling Baizhu Pill on patients with irritable bowel syndrome(IBS).Methods Ninety patients with IBS were collected and divided into Chinese patent medicine group and western medicine group by random number method,45 patients in each group,the Chinese patent medicine group received Shenling Baizhu pill group treatment,the western medicine group was gave Smectite Powder treatment.The changes of clinical symptoms,intestinal tract microorganism and serum inflammatory factor of patients were observed and compared between two groups before and after treatment.The clinical symptoms was evaluated by questionnaire, the Lactobacillus,Bifidobacterium,enterobacteria and yeast were determined by cultivation,the levels of IL -10,IL -18 and TNF -αwere detected by enzyme linked immunosorbent assay(ELISA).Results Two groups before treat-ment of anaerobic bacteria in feces reduction,aerobic bacteria increased serum IL -18 and TNF -alpha content, increased,the content of IL -10 decreased.Shenling Baizhu Pill intervention for 8 weeks in patients with intestinal anaerobic bacteria[(B/E 1.07 ±0.49)]and serum IL -10[(43.65 ±9.52)mg/L]content increased,aerobic bacte-ria[(B/E 1.07 ±0.49)],IL -18[(82.06 ±21.07)mg/L]and TNF -alpha[(28.44 ±10.20)mg/L]decreased. The IL -18 decreased the most,was different with the western medicine group,there was a statistical significance(t =9.926,P <0.01).Two groups had no bad reaction.Conclusion Shenling Baizhu Pill can effectively regulates and improves the intestinal micro -environment,promote the growth of intestinal probiotics and remodeling the intestinal function of biological barrier,decrease the levels of proinflammatory factors and rise the anti -inflammatory factors level,which has a good clinic effect in treating IBS.
6.Role of Sp Family Transcription Factors in Growth Hormone Receptor Gene Expression.
Jeong Won SHIN ; Jae Hong YU ; Ren Zhe AN
Journal of Korean Society of Pediatric Endocrinology 2000;5(2):151-162
PURPOSE: The growth hormone receptor(GHR) is essential for the actions of growth hormone on postnatal growth and metabolism. GHR transcripts are characterized by the presence of disparate 5'untranslated exons. In contrast to L1 transcript, factors regulating the expression of the GC rich L2 transcript have remained unidentified. The purpose of this study is in order to characterize the mechanisms regulating expression of the L2 transcript in the murine GHR gene METHODS: Transient transfection experiments including deletional analysis and co-transfection assay were performed to find a region containing promoter activity in the L2 5'flanking sequence using BNCL2(mouse liver) cells, CV-1(African green monkey kidney) cells, HRP.1 trophoblasts and Drosophila Schneider(SL2) cells. Sequencing analysis was performed to find the region contained consensus binding sites for transcription factors. Standard gel shift(Electrophoretic mobility shift assay, EMSA) and supershift analysis using liver nuclear extracts was performed to establish proteins(transcription factors) bound this regulatory element. RESULTS: The 5'flanking region of the L2 untranslated region(UTR) exhibited promoter activity in BNCL2(mouse liver), CV-1(monkey kidney) cells and HRP.1 trophoblasts. Deletional analyses indicated the presence of a Sp binding site important for transcription of the L2 UTR and localized the major regulatory region within 75 bp of the 5'transcription start site. Sequencing analyses revealed the region contained consensus binding sites for the Sp family of transcription factors. EMSA and supershift EMSA revealed that in mouse liver nuclear extracts that Spl and Sp3 bound to this cis-element. Functional studies in Drosophila SL2 cells and BNCL2(mouse liver) cells established the ability of Sp3 and Sp1 to stimulate transcriptional activity via this cis-element. Functional studies in Drosophila SL2 cells demonstrated a functional interaction between Sp3 and Sp1 at this DNA-binding site. CONCLUSION: Sp family transcription factors play a role in regulation of L2 transcript gene expression in the 5'flanking region of the murine GHR gene.
Animals
;
Binding Sites
;
Cercopithecus aethiops
;
Consensus
;
Drosophila
;
Electrophoretic Mobility Shift Assay
;
Exons
;
Gene Expression
;
Growth Hormone*
;
Humans
;
Liver
;
Metabolism
;
Mice
;
Receptors, Somatotropin*
;
Regulatory Sequences, Nucleic Acid
;
Transcription Factors*
;
Transfection
;
Trophoblasts
7.Neuroprotective Effect of Growth Hormone in Neonatal Rat with Hypoxic Ischemic Brain Injury.
Jae Hong YU ; Kyu Sang SONG ; Ren Zhe ANN
Journal of Korean Society of Pediatric Endocrinology 2001;6(2):147-153
PURPOSE: To investigate the neuroprotective effect of growth hormone(GH) on neuronal cell necrosis and apoptosis at 1 week and 3 weeks after hypoxic ischemic brain injury. METHODS: Sprague-Dawley rats, seven-day-old, were used. Rats were anesthetized with ether less than 5 minutes. The right carotid artery was cut between double ligation. And then, rats were allowed to recover for 30 minutes followed by exposure to 8% oxygen at 37 degrees C for 2 hours for hypoxic ischemic insult. The study group was divided into 2 groups, control group(N=3) and GH treated group(N=3). GH treated group received intraperitoneal injection of GH 1 IU 2 hours after hypoxic ischemic insult following daily adminstration as same dose for 5 days. Rats were decapitated at 1 week and 3 weeks after hypoxic ischemic brain injury. After then, right hippocampal CA1 and CA3 neurons of rat brains were examined. RESULTS: Necrosis was significantly less in GH treated group than control group, and was more prominent at 3 weeks in both groups. The apoptosis was not found in GH treated and control group. CONCLUSION: GH has a neuroprotective effect on neuronal cell deaths(especially necrosis) from 1 week to 3 week after hypoxic ischemic insult in neonatal rat.
Animals
;
Apoptosis
;
Brain Injuries*
;
Brain*
;
Carotid Arteries
;
Control Groups
;
Ether
;
Growth Hormone*
;
Injections, Intraperitoneal
;
Ligation
;
Necrosis
;
Neurons
;
Neuroprotective Agents*
;
Oxygen
;
Rats*
;
Rats, Sprague-Dawley
8.Clinical Observation of Ebastine Combined with Chushi Zhiyang Ointment in the Treatment of Hand Keratin-izing Chapped Eczema
Ying ZHENG ; Jianjun REN ; Weihong HUO ; Juan LIANG ; Zhe ZHOU
China Pharmacy 2016;27(26):3697-3699
OBJECTIVE:To observe clinical efficacy and safety of Ebastine tablet combined with Chushi zhiyang ointment in the treatment of hand keratinizing chapped eczema. METHODS:135 cases of hand keratinizing chapped eczema were divided into control group A(45 cases),control group B(43 cases)and treatment group(47 cases)according to treatment regimen. Control group A was orally given Ebastine tablet,10 mg each time,qd;control group B was given Chushi zhiyang ointment alone,twice a day,morning and evening,applying thin layer of ointment on the affected area;treatment group was given same dose of Ebastine tablet orally and applied Chushi zhiyang ointment on the affected area. 3 groups received treatment for consecutive 4 weeks. Clinical efficacies of 3 groups were observed as well as the scores of pruritus,skin lesion area,keratinization,rhagades and VAS before and after treatment. The occurrence of ADR was compared among 3 groups. RESULTS:The total effective rate of treatment group was 68.09%,which was significantly higher than that of group A(42.22%)and control group B(16.28%),with statistical significance(P<0.05). There was no statistical significance in the scores of pruritus,skin lesion area,keratinization,rhagades and VAS among 3 groups before treatment(P>0.05). After treatment,above scores of 3 groups decreased significantly,and those of treatment group were significant-ly lower than those of control group A and B,with statistical significance(P<0.05). There was no statistical significance in the inci-dence of ADR among 3 groups(P>0.05). CONCLUSIONS:Ebastine tablet combined with Chushi zhiyang ointment is effective for hand keratinizing chapped eczema,and can significantly improve the skin of patients with good safety.
9.Mechanism of fatty liver induced by high-fructose-feeding in rats and intervention effect of fenofibrate
Yang LI ; Zhe GAO ; Luping REN ; Pu ZHANG ; Guangyao SONG
The Journal of Practical Medicine 2017;33(14):2287-2290
Objective To observe the effect of fenofibrate intervention on high-fructose-feeding-induced liver steatosis in rats and explore the possible mechanism. Methods Male Wistar rats were randomly divided into control group ,high fructose group and fenofibrate group[fenofibrate intervention started after 8 weeks of high fructose feeding ,30 mg/(kg · d)]. Rats were sacrificed after 12-week of high fructose feeding. Serum alanine aminotransferase(ALT),aspartate aminotransferase(AST),total cholesterol(TC),free triglyceride(TG)and liver TG content were determined;protein levels of fatty acid synthase(FAS),endoplasmic reticulum stress mark-er Bip and autophagy markers such as Atg7,Beclin1,LC3 and the related pathway mTOR in liver tissues were de-tected. Results Compared with those in control group and fenofibrate group,serum AST,serum total cholesterol, blood free TG and hepatic TG were significantly increased in high-fructose group(P < 0.01). The protein expres-sion of Fas,Bip and mTOR were significantly increased in high-fructose group compared with those in control group and fenofibrate group;the protein expression of Atg7,beclin1 and LC3 were significantly decreased in high-fructose group compared with those in control group and fenofibrate group. Conclusions Long-term high-fructose-feeding induces fatty liver and liver cell injury ,and may affect ERS and autophagy. High-fructose-feeding-in-duced fatty liver may be improved by fenofibrate and its underlying mechanism might be associated with Fas,ERS and autophagy in liver.
10.Recent advances in anti-basic fibroblast growth factor antibody
Zhe REN ; Rude YANG ; Yifei WANG ; Jian LIN
Chinese Journal of Pathophysiology 1986;0(03):-
Basic fibroblast growth factor (bFGF) has been used in wound healing, bone healing, vascular grafting, lens regeneration and limp regeneration. Anti-bFGF antibody is thought to be an major important reagent for bFGF research. This review summarizes the development of anti-bFGF antibody in recent years including preparation, screening, identification and application in order to provide reference to the studies of this field in our country.